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        Ischemic heart disease is a worldwide health 
problem and, in consequence, heart failure has 
emerged as a leading cause of morbidity and mor-
tality (  1  ). Myocardial infarction (MI) and ische-
mic cardiomyopathy are typifi  ed by the irreversible 
loss of cardiomyocytes and vasculature, which are 
essential for maintaining cardiac integrity and 
function. The recent identifi  cation of stem and 
progenitor cells has triggered attempts to directly 
regenerate or repair these tissues by cell transplan-
tation. Provocative and hopeful reports describing 
examples of cardiac regeneration with BM-de-
rived stem (  2  –  4  ) and progenitor cells (  5, 6  ) have 
furthered enthusiasm for the use of these cells, yet 
many questions remain regarding their therapeu-
tic potential and the mechanisms responsible for 
these therapeutic eff  ects. In earlier studies, the 
transdiff  erentiation of stem or progenitor cells 
into cardiomyocytes or endothelial cells (ECs) 
had been proposed as the primary mechanism un-
der  lying the therapeutic benefi  ts of cell transplan-
tation (  2, 3, 5, 7 ). However, recent experimental 
studies using transgenic animal models and imag-
ing techniques have raised questions regarding the 
magnitude or presence of the transdiff  erentiation 
of BM-derived hematopoietic stem or progen-
itor cells (  8  –  10  ). Acknowledging that there are 
diff  erences with regard to study designs, technical 
diff  erences, and types of transplanted cells used 
among diff  erent studies, the notion that durable 
engraftment and transdiff  erentiation of trans-
planted cells are primarily responsible for thera-
peutic eff  ects is now being challenged (  11  –  14  ). 
  Meanwhile, a paracrine mechanism has been 
pro  posed as an additional or alternative mechanism 
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  Noncellular differentiation effects have emerged as important mechanisms mediating 
therapeutic effects of stem or progenitor cell transplantation. Here, we investigated the 
expression patterns and sources of humoral factors and their regional and systemic biologi-
cal effects after bone marrow (BM)-derived endothelial progenitor cell (EPC) transplanta-
tion into ischemic myocardium. Although most of the transplanted EPCs disappeared within 
a week, up-regulation of multiple humoral factors was sustained for longer than two 
weeks, which correlated well with the recovery of cardiac function. To determine the source 
of the humoral factors, we injected human EPCs into immunodefi  cient mice. Whereas the 
expression of human EPC (donor)-derived cytokines rapidly decreased to a nondetectable 
level within a week, up-regulation of mouse (recipient)-derived cytokines, including factors 
that could mobilize BM cells, was sustained. Histologically, we observed higher capillary 
density, a higher proliferation of myocardial cells, a lower cardiomyocyte apoptosis, and 
reduced infarct size. Furthermore, after EPC transplantation, BM-derived stem or progeni-
tor cells were increased in the peripheral circulation and incorporated into the site of 
neovascularization and myocardial repair. These data indicate that myocardial EPC trans-
plantation induces humoral effects, which are sustained by host tissues and play a crucial 
role in repairing myocardial injury. 3258 HUMORAL EFFECTS OF EPCS IN THE ISCHEMIC HEART | Cho et al.
    RESULTS   
  Myocardial EPC transplantation induces prolonged 
expression of multiple humoral factors 
  To determine the levels of expression of various cytokines in 
the myocardium after EPC transplantation, we induced MI in 
C57BL/6 mice by coronary ligation and transplanted 5   ×   10  5   
cultured mouse EPCs directly into the ventricular wall of the 
peri-infarct area. PBS was injected as a control. Mice were killed, 
and cardiac tissues were harvested from the peri-infarct border 
zone at baseline (before MI, day 0) and 1, 7, 14, 28, and 42 d 
after treatment. We measured mRNA levels of multiple angio-
genic, antiapoptotic, and chemoattractant cytokines in myocar-
dium using quantitative real-time RT-PCR (qRT-PCR). The 
patterns of expression varied according to each factor and 
time (  Fig. 1 A  ).   At day 1, MI itself (PBS injection) induced an 
overall increase in cytokine expression, and EPC transplantation 
signifi  cantly augmented such response. At day 7, although the 
expression levels of VEGF-A, fi  broblast growth factor (FGF)-2 
(bFGF), and insulin-like growth factor (IGF)-1 fell below base-
line levels in the PBS group, baseline levels were maintained 
in the EPC-transplanted group. Hepatocyte growth factor (HGF) 
and angiopoietin (Ang)-1 levels increased mildly over 14 d 
for the therapeutic eff  ects of stem or progenitor cells in ische  mic 
cardiovascular disease (  15  ). In contrast to the hype of pre-
clinical and early clinical studies of cell therapy in MI, little is 
known about the expression of paracrine factors and the resul-
tant eff  ects in vivo after cell transplantation in this condition. 
Although Gnecchi et al. (  16  ) investigated this paracrine mecha-
nism, they used Akt-transfected mesenchymal stem cells and did 
not directly measure paracrine factors. In addition, other studies 
investigating the paracrine eff  ects of endothelial progenitor cells 
(EPCs) or mononuclear cells have been limited to in vitro assays 
and/or a hindlimb ischemia model (  15, 17, 18  ). Because the 
paracrine eff  ects of transplanted cells in vivo are variable accord-
ing to the type of administered cells, the type of disease models, 
the route and timing of cell administration, etc., we determined 
to investigate these eff  ects with the use of EPCs in a setting of 
acute MI, which is one of the most common candidates for cell 
therapy in the cardiovascular fi  eld. In this study, we used the term 
  “  humoral  ”   rather than   “  paracrine  ”   to broadly cover the secretory 
aspects of cells because autocrine interaction among transplanted 
cells or systemic action of transplanted cells could also confound 
these effects. We selected BM-derived EPCs for this study 
because EPCs are prototype progenitor cells and one of the most 
widely investigated cell types. EPCs are characterized by sharing 
hematopoietic stem cell (HSC) markers, such as c-kit and Sca-1 
in mice and CD34 and CD133 in humans, but distinctly express-
ing vascular endo  thelial growth factor (VEGF)R-2 (  19  –  21  ). 
Prior studies demon  strated that culture-expanded EPCs were 
therapeutically eff  ective in repairing limb ischemia and MI, and 
incorporation and transdiff  erentiation of transplanted EPCs into 
the neovasculature were considered major mechanisms under-
lying the therapeutic eff  ects (  7, 22  ). 
  Accordingly, we sought to investigate whether multiple 
humoral factors are modulated after EPC transplantation in 
an MI model, and whether these factors are responsible for 
certain therapeutic mechanisms that are diffi   cult to explain by 
transdiff  erentiation of EPCs. We focused on examining rep-
resentative humoral factors, the duration of their expression 
in myocardium, the source of these factors, and the resultant 
biological eff  ects at the cellular level. To meet this end, we 
adopted certain novel approaches. For example, we trans-
planted human EPCs into athymic mice to identify the source 
of cytokines. We also used a mouse BM transplantation (BMT) 
model in which BM was reconstituted with GFP-expressing 
cells to track the fate of BM-derived cells in the infarcted myo-
cardium after myocardial EPC transplantation. In this study, 
we found that myocardial transplantation of EPCs augmented 
various humoral factors involved in angiogenesis, antiapoptosis, 
and chemoattraction of BM cells. Intriguingly, these factors 
were highly expressed in myocardium even after the point at 
which most of the transplanted cells had disappeared, and up-
regulation in this phase was due to recipient cells. Finally, these 
humoral eff  ects promoted proliferation of host myocardial cells, 
attenuated apoptosis of jeopardized cardiomyocytes, and aug-
mented homing of BM-derived stem and/or progenitor cells 
into the ischemic myocardium, which provided a favorable 
milieu for ongoing neovascularization. 
    Figure 1.         Temporal expression patterns of multiple cytokines in 
peri-infarct myocardium after EPC transplantation.   (A) qRT-PCR was 
performed to measure the level of gene expression from the samples 
harvested from the peri-infarct myocardium of C57BL mice at baseline 
(before MI, day 0), 1, 7, 14, 28, and 42 d after MI. Compared with the PBS-
injected hearts, hearts transplanted with syngeneic mouse EPCs expressed 
higher levels of measured cytokines during the study period. Of note, 
cytokine levels were maintained at, or higher than, baseline levels for at 
least 14 d only in the EPC-transplanted hearts (  n   = 5 per group). *, P   <   0.05; 
**, P   <   0.01. (B and C) Immunoblots (B) and their quantifi  cation (C) showed 
that the protein levels of VEGF correlated well with the mRNA expression 
levels (  n   = 3 per group). *, P   <   0.05; **, P   <   0.01.     JEM VOL. 204, December 24, 2007 
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  Engrafted EPCs fade away within a week 
after transplantation 
  To investigate engraftment characteristics of transplanted cells in 
the infarcted myocardium, we injected cells immediately after 
MI, when the engraftment and infl  ammatory signals are stron-
ger. Because studies have demonstrated that more cells are 
retained within the myocardium after intramyocardial versus 
intravenous injection, we selected intramyocardial delivery 
for this study (  11, 23  ). To track the engrafted cells, EPCs from 
enhanced GFP (eGFP) mice with a C57BL/6 background 
were transplanted into wild-type syngeneic mice. Cardiac tissues 
were harvested at days 3, 7, and 14 after cell transplantation 
and were subjected to immunohistochemistry (IHC) (  n   = 4, at 
each time point) (  Fig. 3 A  ).   In the peri-infarct border zone, we 
observed robust engraftment of EPCs 3 d after transplantation, 
which faded away over 7  –  14 d. Next, to further confi  rm the 
disappearance of engrafted cells using a more specifi  c method, we 
performed fl  uorescent in situ hybridization (FISH) using a 
Y chromosome probe. For these experiments, we transplanted 
male EPCs into female mice and harvested cardiac samples. 
FISH revealed that the number of Y chromosome signals were 
signifi  cantly higher at day 3 and gradually decreased over 14 d, 
further confi  rming the results of IHC (  Fig. 3 B  ). We also ex-
plored the potential of EPCs for transdiff  erentiation. At day 14, 
a small fraction of EPCs expressed an endothelial phenotype 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20070166/DC1). Intriguingly, qRT-PCR data revealed 
that humoral activities were sustained   >  14 d. Collectively, these 
data suggest that, even without having many remaining en-
grafted cells, humoral activities can be sustained. This discrep-
ancy led us to further investigate the role of humoral factors in 
mediating therapeutic eff  ects of cell transplantation. 
  Multiple angiogenic and antiapoptotic factors 
are up-regulated after EPC transplantation 
  First, to confi  rm and extend our cytokine studies, we deter-
mined to measure wider varieties of cytokines at both mRNA 
and protein levels and included an EC-transplanted group as an-
other control to rule out the nonspecifi  c eff  ects of cell transplan-
tation. We induced MI in mice and randomly assigned them into 
an EPC, EC, or PBS group (  n   = 5, each group). Surgeries and 
treatment were conducted in an identical fashion to the above 
experiments. Mice were killed at 2 wk, and cardiac tissues were 
harvested for the following studies. qRT-PCR showed that 
various angiogenic factors such as VEGF-A and FGF-2 were 
signifi  cantly up-regulated in the EPC transplantation group 
compared with the PBS- and EC-treated groups (  Fig. 4 A  ).   
Other angiogenic factors such as Ang-1, Ang-2, placenta growth 
factor (PlGF), and HGF were also signifi  cantly up-regulated. 
Interestingly, Ang-2 was increased by 4.4-fold, whereas Ang-1 
increased by 2.0-fold in the EPC group compared with the PBS 
group. We noted relative predominance of Ang-2 to Ang-1, 
i.e., reversal of Ang ratios in favor of Ang-2 in EPC-transplanted 
hearts, which were reported to be an evidence of a proangio-
genic microenvironment (  24, 25  ). Furthermore, antiapoptotic 
and cardiomyogenic factor IGF-1 was signifi  cantly up-regulated. 
after MI in the PBS group, but they went up to supraphysio-
logic levels in the EPC group. Uniquely, the level of stromal 
cell  –  derived factor (SDF)-1 expression after MI signifi  cantly 
increased until day 7 in the PBS group compared with the base-
line level, and EPC transplantation further increased SDF-1 
levels. Overall, all the measured cytokines were more highly 
expressed in the EPC-transplanted hearts compared with the 
PBS-injected hearts for at least 14 d. Although the expression 
levels of various cytokines reached their nadir between 7 and 
14 d in the PBS group, the changes continued for 14 d and 
reached their nadir between 28 and 42 d in the EPC group. 
These data suggest that EPC transplantation not only augments 
an initial surge of cytokines after MI, but exerts prolonged 
humoral eff  ects. Next, to verify the correlation between the 
mRNA and protein levels, we serially measured protein expres-
sion of one representative humoral factor, VEGF, by Western 
blotting. Immunoblots showed that the levels of VEGF were 
consistently higher in the EPC group compared with the PBS 
group over 28 d, and the protein levels correlated well with the 
mRNA levels (  Fig. 1, B and C  ). 
  Therapeutic effects of EPC transplantation occur 
over the fi  rst 2 wk 
  To investigate the temporal relationship between these cyto-
kines and cardiac function, we performed echocardiography 
every week for 6 wk after MI and treatment (  Fig. 2  ).   Echocar-
diography showed that from 2 wk after treatment, left ventricle 
(LV) dimensions at both systole and diastole were signifi  cantly 
smaller in the EPC group than in the PBS group (  n   = 7 in each 
group) (  Fig. 2, A and B  ), and LV fractional shortening was 
better in the EPC group accordingly (  Fig. 2 C  ). These fi  ndings 
suggest that EPC transplantation attenuates adverse ventricular 
remodeling within 2 wk after MI and prevents cardiac dys-
function in the long run. Furthermore, the time course of 
cardiac functional improvement correlated well with the 
temporal expression patterns of the measured cytokines. There-
fore, in the following series of experiments, we determined 
to focus on the molecular and histopathologic changes over 
the fi  rst 2 wk. 
    Figure 2.         Therapeutic effects of EPC transplantation occur within 
the fi  rst 2 wk.   Cardiac function measured by M-mode echocardiography 
was better in EPC-transplanted hearts compared with the control from 2 wk 
after MI represented by smaller LV end systolic dimension (LVESD) (A) and 
LV end-diastolic dimension (LVEDD) (B), and greater fractional shortening 
(C) (  n   = 7 per group). *, P   <   0.05.     3260 HUMORAL EFFECTS OF EPCS IN THE ISCHEMIC HEART | Cho et al.
of multiple humoral factors associated with angiogenesis, anti-
apoptosis, cell proliferation, and BM mobilization both at the 
mRNA and protein levels for at least 2 wk. 
  Sustained up-regulation of humoral factors is attributed 
to host tissues 
  From these repeated experiments, it seems clear that these 
representative cytokines, which are known to be benefi  cial 
for cardiac repair, were up-regulated despite scant cellular 
An arteriogenic factor, platelet-derived growth factor (PDGF)-B, 
and a well known chemoattractant factor, SDF-1, were also up-
regulated. Next, we performed immunoblots to examine the pro-
tein expression of representative factors such as VEGF, FGF-2, 
IGF-1, PDGF-B, and SDF-1 in the same cardiac tissues (  Fig. 
4 B  ). The levels of these proteins were also elevated in the EPC 
group compared with the control groups, indicating good cor-
relation with mRNA expression levels. Collectively, these fi  nd-
ings indicate that EPC transplantation up-regulates the expression 
    Figure 3.         Engrafted EPCs faded away within a week after transplantation.   (A) EPCs isolated from GFP-expressing mice were injected directly 
into the myocardium of wild-type mice. Shown are the histological sections of myocardium harvested at predetermined time points. Despite the robust initial 
engraftment of transplanted EPCs (green) at day 3, a majority of transplanted cells faded away within a week, and only a few transplanted cells were detected 
in the peri-infarct area at days 7 and 14. green, GFP; red, anti  –      -sarcomeric actinin; blue, DAPI. (B) Representative fi  gures from serial cardiac samples 
(days 3, 7, and 14) obtained from female mouse hearts transplanted with male mouse EPCs (wild-type). The panels show a gradual decrease of transplanted 
EPCs over 14 d. Red fl  uorescence within DAPI  +   nuclei (blue) represents Y chromosome signals detected by FISH. Bars: A, 200     m; B, 20    m.   
    Figure 4.         Multiple humoral factors are up-regulated after EPC transplantation.   (A) qRT-PCR using tissues obtained from the peri-infarct myocar-
dium of wild-type mice at day 14 after treatment demonstrated that various angiogenic, antiapoptotic, and chemoattractant cytokines were up-regu-
lated in the mouse EPC-transplanted hearts compared with the PBS- or mouse EC  –  injected hearts. Individual values were normalized to GAPDH. Data are 
presented as fold difference compared with the PBS group (  n   = 8 per group). *, P   <   0.05; **, P   <   0.01. (B) Immunoblots showed that representative 
humoral factors were also up-regulated at the protein level. Protein expression correlated well with mRNA expression. Blots represented at least four 
independent experiments.     JEM VOL. 204, December 24, 2007 
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P   <   0.01). Furthermore, we studied the pro-proliferative eff  ects 
of EPC transplantation because cytokines related to cardiomyo-
cyte protection and proliferation such as IGF-1 and PDGF-B 
were up-regulated. From tissue sections obtained at day 14, 
we counted cells stained positive for Ki-67. Ki-67 is known 
to be expressed in all active parts of the cell cycle (G1, S, G2, 
and mitosis), but not in G0 (  26, 27  ). The number of prolifer-
ating cells was 10 times higher in the EPC-transplanted hearts 
compared with the control groups in the peri-infarct zone 
(  Fig. 6, C and D  ) (EPC group vs. EC group and PBS group: 
79.7   ±   15.3/mm  2   vs. 7.55   ±   2.7/mm  2   and 5.66   ±   2.7 /mm  2  ; 
P   <   0.01). In the EPC group, we observed small, elongated 
    -sarcomeric actinin  +   proliferating cells, suggestive of regen-
erating immature cardiomyocytes originating from resident 
cardiac stem or progenitor cells (  Fig. 6 C  , EPC, bottom). 
  Intramyocardial transplantation of EPCs enhances 
mobilization of endogenous EPCs and HSCs 
  Our fi  nding that EPC transplantation substantially increases 
myocardial expression of VEGF and SDF-1, which are known 
to mobilize HSCs or EPCs from BM (  28, 29  ), prompted us to 
investigate the eff  ects of intramyocardial EPC transplantation 
engraftment at 2 wk. Thus, our next step was to explore the 
source of the increased cytokines. We hypothesized that this 
prolonged increase in biological factors may be due to host cells. 
To distinguish between gene up-regulation by donor cells as 
opposed to recipient cells, we transplanted human EPCs into 
the myocardium of athymic nude mice. The surgical and cell 
transplantation procedures were identical to those described 
in the experiments with mouse EPCs. To detect the origin of 
cytokines, human- and mouse-specifi  c probes and primers were 
designed for each humoral factor, and the specifi  city was tested 
using cultured human EPCs and mouse heart tissues. qRT-
PCR showed no cross-reaction between species-specifi  c primers 
and probes for the same cytokines (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20070166/DC1). Consid-
ering that the infl  ammatory response of immunocompromised 
mice (nude mice) might be diff  erent from that of wild-type 
mice, we performed another preliminary experiment to verify 
whether the expression levels of cytokines in human EPC-
transplanted nude mice are similar to those in mouse to mouse 
experiments. Similar to the experiments conducted in   Fig. 4  , we 
compared the levels of cytokines between human EPC- and 
control (PBS)-injected hearts in nude mice by qRT-PCR. The 
human EPC-injected hearts showed robust up-regulation of 
FGF-2, Ang-2, HGF, IGF-I, and SDF-1, and modest up-regu-
lation of VEGF-A, Ang-1, PlGF, and PDGF-B compared with 
PBS-injected hearts (Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20070166/DC1). The overall pattern 
of expression in immunocompromised mice after human EPC 
transplantation was similar to the results obtained from mouse 
hearts injected with mouse EPCs (Fig. S2 and   Fig. 4 A  ). 
  Next, we serially measured the cytokines with both human- 
and mouse-specifi  c primers and probes. On the whole, the cyto-
kine expressions originating from human EPCs (donor cells) 
peaked at day 1 and declined to an undetectable range within 
7 d, whereas those derived from the mice hearts (recipient cells) 
went up after day 1 and were maintained over 14 d (  Fig. 5  ).   
Collectively, these fi  ndings suggest that the initial up-regulation 
is derived from a combination of transplanted and recipient cells, 
and the sustained up-regulation is attributed to recipient cells, but 
not to transplanted cells. 
  EPC transplantation decreases apoptosis and augments 
proliferation of myocardial cells 
  Next, we examined the eff  ects of increased humoral factors at 
the cell and tissue levels. Because biological factors associated 
with cell survival and antiapoptosis such as VEGF, HGF, and 
IGF-1 were up-regulated, we fi  rst investigated whether trans-
planted cells could aff  ect apoptosis, generally regarded as one of 
the major mechanisms responsible for ongoing myocardial 
degeneration after acute MI. We performed a Tdt-mediated 
dUTP-biotin nick-end labeling (TUNEL) assay with tissue 
sections harvested from the peri-infarct zone at day 7 (  Fig. 6, 
A and B  ).   The number of TUNEL  +   nuclei in the peri-infarct 
zone was almost three times lower in the EPC group than in the 
control groups (EPC group vs. EC group and PBS group: 
19.9   ±   4.9/mm  2   vs. 57.1   ±   10.4/mm  2   and 66.6   ±   16.3 /mm  2  ; 
    Figure 5.         Host cells constitute the major role for sustained 
up-regulation of the humoral factors.   To determine whether the up-regu-
lated cytokines were derived from injected donor cells or recipient host 
cells, human EPCs were transplanted into immunocompromised nude mice, 
and the levels of cytokines were measured by both human- and mouse-
specifi  c primers and probes for each cytokine. The expression levels of cyto-
kines from human EPCs (donor cells) were at their highest levels at day 1 
and fell to an undetectable range within 7 d. Most of the mouse (host)-
specifi  c cytokine levels continued to rise after day 1 and were maintained 
at higher than the baseline levels over 14 d (  n   = 5 per each time point). 
Individual values were normalized to GAPDH and shown as fold difference 
to the values at day 1.     3262 HUMORAL EFFECTS OF EPCS IN THE ISCHEMIC HEART | Cho et al.
Lin       c-kit  +  Sca-1  +   cells, which are regarded as multipotent HSCs, 
was signifi  cantly increased in the EPC group compared with 
the control groups at day 7 (  Fig. 7, E  –  G  ). Collectively, these 
data suggest that myocardial EPC transplantation leads to sig-
nifi  cant mobilization of endogenous EPCs and HSCs into 
peripheral circulation. 
  EPC transplantation augments recruitment of BM-derived 
cells into ischemic hearts, which contributes 
to neovascularization 
  Because we found that endogenous BM-derived stem and pro-
genitor cells are mobilized after myocardial transplantation of 
EPCs, we subsequently evaluated the recruitment and incor-
poration of BM-derived cells into the infarcted myocardium. 
To track the cells derived from BM, we used a BMT model in 
which wild-type mice were lethally irradiated and transplanted 
on mobilization and recruitment of BM-derived cells. First, to 
determine the number of mobilized EPCs in circulation, we 
used two independent measurements: EPC culture assay and 
fl  ow cytometry (FACS) analysis. The EPC culture assay of pe-
ripheral blood showed that the number of circulating EPCs, 
which were defi  ned by uptake of acetylated low density lipo-
protein (LDL) and binding to lectin in culture, was 2 and 3.5 
times higher in the EPC group compared with control groups 
at days 7 and 14, respectively (  Fig. 7, A and B  ).   Although the 
number of circulating EPCs increased over 14 d in the EPC 
group, it decreased rapidly in the EC and PBS groups after day 7. 
FACS analysis also revealed that the number of EPCs, which 
are defi  ned by cells coexpressing VEGFR-2 and Sca-1 epitopes, 
was signifi  cantly higher in the EPC group compared with 
the control groups at day 14 (  Fig. 7, C and D  ). Furthermore, 
FACS analysis demonstrated that the number of circulating 
    Figure 6.         EPC transplantation decreases myocardial apoptosis and augments proliferation of myocardial cells.   (A and B) Concomitant staining 
of EPC-, EC-, and PBS-treated myocardium with     -sarcomeric actinin (red) and TUNEL (green) to identify apoptotic cardiomyocytes (arrows) at day 7 after 
MI (A). Fewer apoptotic cells were evident in the peri-infarct area of mice receiving EPCs compared with those receiving EC or PBS (B) (  n   = 7 per group). 
*, P   <   0.01. (C and D) Identifi  cation of proliferating cells by Ki-67 IHC at 14 d after MI. In myocardial sections, Ki-67  +   cells are demonstrated by green fl  uo-
rescence (C). Proliferating cardiomyocytes with a regular rod shape (EPC, top) and small-sized elongated shape (EPC, bottom) were more frequently observed 
in the EPC group. Quantifi  cation revealed that EPC-transplanted hearts had a signifi  cantly higher number of Ki-67  +   myocardial cells compared with the 
EC- or PBS-injected hearts (  n   = 7 per group). *, P   <   0.01 versus EC and PBS groups. Bars: A, 100     m; C, left and middle, 100     m; C, right, 20    m.   JEM VOL. 204, December 24, 2007 
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fl  uorescent IHC with vessel and muscle markers. Concomi-
tant staining with GFP- and EC-specifi  c markers such as CD31 
(PECAM-1) or isolectin B4 revealed that a portion of GFP  +   
cells were incorporated into vessels and expressed EC mark-
ers, suggestive of transdiff  erentiation of recruited BM-derived 
cells into ECs (  Fig. 8, D and E  , white arrows). Intriguingly, 
GFP  +   cells were more localized in the perivascular and peri-
cytic areas (  Fig. 8, F and G  ). On the other hand, IHC with an-
tibodies against     -sarcomeric actinin and GFP illustrated that 
only rarely did recruited BM-derived cells express a cardio-
myocyte phenotype, and that these showed the morphology 
of immature cardiomyocytes, but not mature cardiomyocytes 
(  Fig. 8, H and I  ). Collectively, these fi  ndings suggest that re-
cruited BM-derived cells contribute to neovascularization 
via direct vascu  logenesis as well as potential augmentation of 
with BM cells of eGFP transgenic mice. 8 wk after BMT, we 
confi  rmed reconstitution of BM. FACS analysis showed that 
  >  90% of peripheral blood mononuclear cells expressed GFP 
(  Fig. 8 A  ).   Then, we performed MI and EPC transplantation in 
an identical fashion and harvested hearts 2 wk after the surgery. 
Fluorescent IHC demonstrated that the number of GFP  +   cells 
in cardiac tissues, which indicate cells derived from transplanted 
BM, was three times higher in the EPC-transplanted group 
compared with the EC- and PBS-injected groups (  Fig. 8, B 
and C  ). These data suggest that EPC transplantation not only 
mobilizes stem and progenitor cells from BM, but also aug-
ments recruitment or homing of these BM-derived cells into 
ischemic myocardium. 
  Next, to determine the contribution of recruited BM cells 
to neovascularization and cardiomyogenesis, we performed 
    Figure 7.         Intramyocardial transplantation of EPCs enhances mobilization of EPCs and stem cells from BM.   (A and B) EPC culture assay of pe-
ripheral blood demonstrated that the number of circulating EPCs, which were defi  ned as adherent cells that showed the characteristics of acetylated LDL 
uptake (red color) and lectin binding (green color), signifi  cantly increased in the EPC group compared with other control groups at days 7 and 14 after MI. 
*, P   <   0.01 versus EC and PBS at day 7; **, P   <   0.01 versus EC and PBS at day 14. (C and D) Flow cytometry analysis showed that the number of double-
positive cells for VEGFR-2 and Sca-1 epitopes was signifi  cantly increased in the EPC group at day 14. *, P   <   0.01 versus EC and PBS groups. (E  –  G) Measure-
ment of circulating lin      c-kit + Sca1 +   cells by fl  ow cytometry analysis. Hematopoietic lineage        cells were selected by R2 gate from peripheral blood 
mononuclear cells after staining with hematopoietic lineage cocktail antibodies (E). Such Lin        cells within the R2 gate were analyzed by c-kit and Sca-1 
markers in EPC, EC, and PBS groups (F). Quantitative analysis showed that Lin      c-kit + Sca-1 +   cells in peripheral circulation were signifi  cantly increased in 
the EPC-transplanted group compared with the control groups at day 7 (  n   = 5 per group). *, P   <   0.05 versus EC and PBS at day 7. Bars: A, 40    m.   3264 HUMORAL EFFECTS OF EPCS IN THE ISCHEMIC HEART | Cho et al.
1,286   ±   91.9 /mm  2   vs. 742   ±   98.2 /mm  2   and 559   ±   92.3 /mm  2  ; 
P   <   0.01) (  Fig. 9, C and D  ). These results suggest that EPC 
transplantation increases myocardial neovascularization and 
induces favorable remodeling of the infarcted heart. 
    DISCUSSION   
  In this study, we addressed the humoral eff  ects of EPC trans-
plantation in the ischemic heart. Some of the most salient 
fi  ndings of the study are as follows. First, we demonstrated that 
direct transplantation of BM-derived EPCs into ischemic hearts 
induces signifi  cant and sustained increase in various angio-
genic, antiapoptotic, and chemoattractant factors during the 
vascular remodeling or angiogenesis. However, the contribu-
tion to direct cardiomyogenesis appears minimal. 
  EPC transplantation decreases infarct size and increases 
capillary density 
  Finally, to determine pathological changes after EPC trans-
plantation, we measured fi  brosis area and capillary density with 
2-wk samples. Picrosirius red staining revealed that fi  brosis was 
significantly reduced in the EPC group (  Fig. 9, A and B  ).   
Furthermore, isolectin B4 staining showed that capillary den-
sity was signifi  cantly higher in the EPC group than in the 
control groups (EPC group vs. EC group and PBS group: 
    Figure 8.         EPC transplantation augments incorporation of BM-derived cells into ischemic hearts.   (A) After lethal irradiation, the BM of wild-type 
mice was reconstituted with BM cells isolated from eGFP transgenic mice. 8 wk after BMT, fl  ow cytometry analysis showed that   >  90% of peripheral 
blood mononuclear cells expressed GFP protein, suggesting successful reconstitution of BM. (B) At day 14 after induction of MI in these chimeric mice, the 
recruited cells from BM to the peri-infarct area were evaluated. Green, GFP; red,     -sarcomeric actinin; blue, DAPI for nuclei. (C) Quantifi  cation of GFP  +   cells 
showed that EPC transplantation signifi  cantly augmented the incorporation of BM-derived cells into the peri-infarct area (  n   = 5 per group). *, P   <   0.01 versus 
EC and PBS at day 14. (D  –  G) IHC with Isolectin B4 (D, red) or CD31 (E  –  G, red) revealed the localization of BM-derived GFP  +   cells within and around the 
vasculature in the peri-infarct area at day 14 after MI. White arrows indicate GFP  +   cells, which are both incorporated into vasculature and colocalized with 
ECs, suggestive of transdifferentiation. A white arrowhead points to the pericytic localization of GFP  +   cells, and a yellow arrow illustrates perivascular 
localization of GFP  +   cells. The majority of GFP  +   cells were located in the pericytic (F) and perivascular area (G). (H) IHC with     -sarcomeric actinin (red) revealed 
that the majority of BM-derived cells did not exhibit a cardiomyocyte phenotype. (I) Rarely, a few GFP  +   cells (arrow) showed immature cardiomyocyte mor-
phology. Bars: B, 100    m;  D – I,  20    m.   JEM VOL. 204, December 24, 2007 
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autocrine eff  ects and remote secretory eff  ects of stem cells, are 
excluded when using the term paracrine. Therefore we adopted 
the term   “  humoral  ”   in this study. We assumed that if experi-
ments are designed to study the humoral aspect of cell trans-
plantation, biological factors would need to be measured in 
vivo in a time-dependent manner. Also, the representative 
biological eff  ects at the cellular and tissue levels need to be 
investigated together with pathophysiological changes of the 
heart. In our study, we followed this rationale and demon-
strated that multiple angiogenic, antiapoptotic, cardiomyo-
genic, and chemoattractant factors are signifi  cantly increased in 
EPC-transplanted hearts. Moreover, we fi  rst revealed that the 
time course of the humoral factors correlated well with the 
functional improvement and favorable cardiac remodeling 
after MI. Another useful insight was obtained by measur-
ing cytokines at multiple time points. We newly discovered 
that direct transplantation of EPCs sustains the favorable hu-
moral eff  ects longer than 14 d, which is regarded as the most 
critical period for determining the fate of cardiac remodeling 
after acute MI (  5, 36  ). 
  On the other hand, comparative analysis of data on en-
graftment and gene expression allowed us to identify the 
source of up-regulated cytokines, which is one of the most in-
triguing parts of this study. Classically, the transplanted cells 
were thought to be a major source of paracrine factors. Previ-
ous studies showed that multiple cytokines were increased in 
the conditioned media of BM-MNC, EPC, and mesenchymal 
stem cell cultures, and suggested the potential role of released 
cytokines in mediating therapeutic eff  ects (  16, 17, 34  ). How-
ever, no studies broadly addressed the temporal changes, their 
biological signifi  cance, and the role of these factors in the con-
text of myocardial ischemia. In this study, we used a compre-
hensive approach of physiological, immunohistochemical, and 
molecular methods to investigate this secretory property of 
progenitor cells. We noted that, although the majority of 
transplanted cells had disappeared precipitously within the fi  rst 
week after cell transplantation, most of the benefi  cial biologi-
cal factors were still up-regulated 2 wk later. This discrepancy 
led us to ask if such factors may be derived from host cells. We 
thus examined the expression levels of the same cytokines with 
two diff  erent sets of primers and probes for each cytokine, de-
signed to detect either human or mouse specifi  c mRNAs, and 
found that there are dual sources of humoral factors, such that 
initial up-regulation is caused by transplanted and host cells and 
sustained up-regulation is due to host cells or tissues. 
  For the origin of host-derived cytokines after cell trans-
plantation, at least two sources are available: one from resident 
tissue cells and the other from recruited BM-derived cells. In 
our model, it is probable that both myocardium and recruited 
BM cells contribute to the sustained increase of humoral factors. 
One recent study showed that implanted BM-MNCs in a 
hindlimb ischemia model did not secrete suffi   cient angiogenic 
factors to induce neovascularization, but instead, the stim-
ulated muscle cells produced angiogenic factors (  37  ). That 
study indicated that the resident muscle cells, but not trans-
planted cells, could be a major source of angiogenic cytokines. 
critical period of infarct repair and remodeling. Second, we 
disclosed for the fi  rst time that up-regulation of biological 
factors after EPC transplantation in ischemic hearts comprises 
two phases: the initial phase of up-regulation attributed to a com-
bination of transplanted and host cells, and the sustained phase 
of up-regulation attributed primarily to host cells. Third, myo-
cardial EPC transplantation further mobilizes endogenous BM-
derived stem and progenitor cells into peripheral circulation, 
recruiting them into the ischemic myocardium, and thereby 
providing an additional favorable milieu for neovascularization 
and repair or regeneration of ischemic myocardium. 
  Cell therapy with BM-derived cells for ischemic heart 
disease has already been introduced into clinical trials (  30  –  32  ). 
Although cell therapy has emerged as a promising therapeutic 
modality, there has been some controversy on the underlying 
mechanisms. One of the most important debates lies in the 
plasticity of BM-derived stem or progenitor cells, i.e., whether 
or not transdiff  erentiation occurs (  2, 3, 7  –  9, 33  ). Despite the 
reported therapeutic benefi  t of BM-derived stem or progeni-
tor cells, more recent studies demonstrated that the extent 
and the durability of transdiff  erentiation are not suffi   cient to 
explain the entire therapeutic eff  ects of cell therapy (  4, 15  –  17  ). 
In the meantime, a paracrine mechanism has emerged as an 
alternative or additional mechanism to explain this discrep-
ancy. BM cells are known as a natural source of multiple cyto-
kines involved in angiogenesis. Release of multiple cytokines 
from BM cellular components, including whole BM-derived 
mononuclear cells (BM-MNCs) (  34  ), HSCs (  35  ), mesenchymal 
stem cells (  15, 16  ), and EPCs (  17  ), was demonstrated in previ-
ous reports. However, the term   “  paracrine  ”   seems to be too 
restricted to encompass the broad secretory components of 
stem cell effects in vivo. For example, cell  –  cell interaction 
among transplanted cells via secretary molecules, including 
    Figure 9.         EPC transplantation decreases infarct size and increases 
capillary density.   (A) Representative picrosirius red staining of hearts 14 d 
after MI. The red color represents fi  brosis. (B) EPC transplantation signifi  -
cantly reduced percent circumferential fi  brosis (  n   = 7 per group). *, P   <   0.05. 
(C) Isolectin B4 staining in the peri-infarct area (red color) at day 14. (D) EPC 
transplantation signifi  cantly increased capillary density (  n   = 7 per group). 
*, P   <   0.01 versus EC and PBS groups. Bars: C, 100    m.   3266 HUMORAL EFFECTS OF EPCS IN THE ISCHEMIC HEART | Cho et al.
endothelium at the site of neovascularization even at 2 wk 
after EPC transplantation. Although the exact colocalization 
with the endothelium was relatively infrequent, we observed 
accumulation of more BM-derived cells at the perivascular 
and pericytic area (  Fig. 8  ). These fi  ndings were consistent 
with the previous report that proposed the essential paracrine 
role of recruited cells for augmenting neovascularization (  44  ). 
Collectively, these fi  ndings support the importance of pro-
mobilization action of transplanted EPCs in repairing isch-
emic myocardium. 
  The fi  ndings of this study are of interest for a variety of 
scientifi  c reasons. However, the implication of our data resides to 
a large degree on the humoral eff  ect of culture-expanded early 
EPCs in the setting of acute MI. Because defi  nitions of EPCs 
and candidate diseases diff  er widely between studies (  45, 46  ), this 
paradigm alone may not off  er the full explanation for the hu-
moral or paracrine eff  ects in other cell therapy studies. 
  In conclusion, we showed that intramyocardial EPC 
transplantation induces humoral eff  ects that are sustained by 
host tissues and play a crucial role in repairing myocardial in-
jury, and we revealed the importance of cross-talk between heart 
and BM mediated by humoral eff  ects after progenitor cell trans-
plantation for achieving optimal therapeutic eff  ects. Our obser-
vation may further extend to the requirement for healthy BM 
and heart to obtain optimal therapeutic eff  ects after BM-derived 
progenitor cell therapy in acute MI. This may also partly explain 
the diff  erence in results between preclinical experiments per-
formed in healthy animals and clinical trials performed in patients 
with multiple risk factors and diseased myocardium that aff  ect 
the health of BM and myocardium. 
  MATERIALS AND METHODS 
  Animals 
  Wild-type C57BL/6 ubiquitous eGFP-expressing transgenic mice with a 
C57 background (The Jackson Laboratory) and athymic nude mice (Charles 
River Laboratories) aged 6  –  10 wk were used. All experimental protocols 
were approved by Caritas St. Elizabeth  ’  s Institutional Animal Care and Use 
Committee and conformed to the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals. 
  Induction of MI and intramyocardial cell transplantation.     Mice were 
anesthetized with an intraperitoneal injection of avertin (0.014 mg/kg; 
2,2,2-Tribromoethanol; Sigma-Aldrich). Mice were intubated with a 22G 
IV catheter and artifi  cially ventilated with a mechanical ventilator (Harvard 
Apparatus). After a left-sided thoracotomy, the left anterior descending 
artery was ligated just distal to the bifurcation of the diagonal branch using 8  –  0 
polypropylene sutures through a dissecting microscope (  47  ). The apex of the 
LV was observed for evidence of myocardial blanching and akinesia indicat-
ing interruption of coronary fl  ow. After induction of MI, 5   ×   10  5   mouse or 
human EPCs in a volume of 50     l PBS was directly transplanted into the 
peri-infarct areas and apex (total of fi  ve sites) using a 30 G needle. In control 
groups, 5   ×   10  5   strain-matched ECs or the same volume of PBS was injected 
in an identical fashion. At predetermined time points, peripheral blood sam-
ples were obtained and hearts were harvested after mice were killed. 
  BMT model.     To trace BM-derived cells, BMT was performed as described 
previously (  48  ). In brief, each recipient wild-type mouse was lethally irradi-
ated with 1,200 cGy in two equal doses of 600 cGy delivered 3 h apart. 10  6   
BM-mononuclear cells harvested from eGFP mice in a volume of 200     l 
PBS were injected into the tail vein. 
Also, another study recently highlighted the importance of 
BM-derived stem cells in natural infarct repair (  25  ). This study, 
with the use of chimeric mice in which BM was reconsti-
tuted with c-kit mutant mice and thus BM cell mobilization 
was defective, demonstrated that this defect of mobilization 
caused adverse cardiac remodeling after MI and that reconstitu-
tion of BM with wild-type BM cells enhanced cardiac repair. 
Collectively, these studies support the role and importance of 
resident myocardial cells and mobilized BM cells in the repair 
and regeneration of tissues after ischemic injury. Here, our 
study for the fi  rst time demonstrated that humoral eff  ects after 
EPC transplantation provide therapeutic benefi  ts through these 
host-dependent mechanisms. 
  Furthermore, we demonstrated the pro-mobilization and 
-recruitment eff  ects of stem/progenitor cell therapy in this 
study. Of the multiple cytokines that were increased in the 
myocardium after EPC transplantation, we noted that VEGF, 
Ang-1, SDF-1, and PlGF are capable of mobilizing BM cells 
(  38  –  41  ). Next, we hypothesized that these increased cyto-
kines could further mobilize BM-derived cells into circulation 
and facilitate homing of cells into the myocardium. In fact, we 
found that the number of circulating EPCs and Lin       c-kit  + 
Sca-1  +   cells in peripheral circulation was increased in the EPC-
transplanted animals compared with the animals receiving 
PBS or EC, and that more BM-derived cells were recruited 
in the ischemic myocardium. Because these recruited cells 
are again able to either undergo transdiff  erentiation or to pro-
vide cytokines that are involved in angiomyogenesis and BM 
mobilization, this mobilization-recruitment-secretion loop 
appears to play an important role in myocardial repair. Also, we 
noticed that myocardium serves as a depot for important angio-
myogenic factors. Our data in   Fig. 1   revealed that after MI, im-
portant angiogenic and antiapoptotic cytokines such as VEGF-A, 
FGF-2, and IGF-I, which were only mildly elevated due to 
infl  ammatory response after acute MI, decreased quickly below 
the baseline level within 3 d in the border zone due to the loss 
of cardiomyocytes, suggesting that myocardium itself is an 
important secretory organ. Therefore, early preservation of 
myocardial mass is an important target for therapy not only to 
prevent mechanical dysfunction, but also to maintain proper 
secretory function. In this context, high expression of IGF-1 
and HGF after EPC transplantation may play a crucial role in 
preventing adverse remodeling, as these two cytokines are 
known to protect cardiomyocytes from apoptotic cell death and 
induce proliferation of resident cardiac stem cells for neovas-
cularization and cardiomyogenesis (  18, 42  ). 
  We also examined the fate of transplanted EPCs (donor) 
and mobilized BM-derived cells (host-derived cells). Trans-
planted EPCs have been shown to incorporate into neovas-
culature in ischemic injury models (  6, 7, 22  ). However, the 
extent and duration of incorporation of transplanted EPCs 
into host endothelium varies widely among studies (  43  ). In 
our observation, the vast majority of transplanted EPCs dis-
appeared within 1 wk, even though we observed robust en-
graftment at 3 d after cell transplantation. Intriguingly, we 
confi  rmed the contribution of mobilized host BM cells to JEM VOL. 204, December 24, 2007 
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All measurements represented the mean of at least three consecutive car-
diac cycles. 
  Histological analysis 
  Hearts were perfused retrogradely through the right carotid artery with PBS and 
4% paraformaldehyde. The hearts were fi  xed for 4 h in paraformaldehyde and 
incubated overnight in 15% sucrose solution. The tissues were embedded in 
OCT compound (Sakura Finetek), snap-frozen in liquid nitrogen, and sec-
tioned at 5-mm thickness as described previously by our laboratory (4, 47).        To 
measure circumferential fi  brosis area, picrosirius red staining was performed 
(  50  ). Percent fi  brosis length was calculated as the ratio of the length of fi  brosis to 
the length of LV circumference by using a computerized digital image analysis 
system (Image Pro, version 4.5; MediaCybernetics). To trace GFP  +   cells in 
hearts, anti-GFP antibody (Abcam Inc.) was used. To identify capillaries and 
cardiomyocytes, an EC marker Isolectin B4 (Vector Laboratories) or anti-CD31 
antibody (BD Biosciences) and anti  –       sarcomeric actinin antibody or anti  –  tro-
ponin-I (Santa Cruz Biotechnology, Inc.) were used. We used DAPI for nuclear 
counterstaining. To identify male EPCs in the female hearts, FISH was per-
formed with a Cy3-conjugated mouse Y chromosome probe (Cambio). The 
tissue sections were pre-denatured, dehydrated, denatured, and hybridized ac-
cording to the manufacturer  ’  s protocol. To assess apoptosis, TUNEL reaction 
was performed by using the fl  uorescein in situ cell death detection kit (Roche). 
To evaluate proliferative cells, IHC with anti  –  Ki-67 antibody (Novocastra Lab-
oratories) was performed. In the above fl  uorescent IHC, Cy2-, FITC-, Cy3-, 
rhodamine-, or TRITC-conjugated secondary antibodies were applied appro-
priately. For quantifi  cation of apoptosis, capillary densities, and proliferating 
cells, at least four randomly selected fi  elds at both sides of the peri-infarct border 
zone in nonconsecutive tissue sections were examined, and the number of posi-
tive cells in each high-power fi  eld was converted to cells per square millimeter. 
  Statistical analysis 
  All data were presented as mean   ±   SE. Statistical analyses were performed with 
Student  ’  s   t   test for comparisons between two groups, and ANOVA followed 
by Bonferroni  ’  s correction was performed for more than two groups using 
SPSS version 11.0. P   <   0.05 is considered to denote statistical signifi  cance. 
  Online supplemental material 
  Table S1 describes the mouse-specifi  c and human-specifi  c primers and probes 
for qRT-PCR. Fig. S1 shows the specifi  city of these primers and probes. 
Fig. S2 describes the expression patterns of humoral factors in the MI hearts 
of athymic nude mice 14 d after human EPC transplantation. The online 
supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20070166/DC1. 
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  Cell cultures 
  EPC.     For culture of mouse EPCs, BM-MNCs were isolated by density gra-
dient centrifugation with Histopaque-1083 (Sigma-Aldrich) and were plated at 
a density of 0.8  –  1.0   ×   10  6   cells/cm  2   on rat plasma vitronectin  –  coated (Sigma-
Aldrich) dishes with EC basal medium (EBM-2) supplemented with 5% FBS, 
antibiotics, and cytokine cocktail (SingleQuots; Clonetics). Nonadherent cells 
were removed at day 4, and cultures were supplemented with new media. The 
cells were maintained through day 7 and used as EPC-enriched population 
(  7, 22  ). For cultivation of human EPCs, mononuclear cells were isolated with 
Histopaque-1077 (Sigma-Aldrich) from 50 ml of peripheral blood obtained 
from healthy donors and cultured in EPC media as described above. All experi-
ments dealing with human products were conducted with informed consent. 
  EC.     Mature ECs of C57BL/6 mice (MS1, pancreatic islet EC line) were 
purchased (American Type Culture Collection) and cultured in DMEM 
media supplemented with   l-  glutamine, 10% FBS, and antibiotics. 
  qRT-PCR and immunoblotting 
  Peri-infarct myocardial tissues were harvested and pulverized to extract RNA 
or protein. Total RNA was extracted with the use of RNA-Stat (Iso-Tex 
Diagnostics) according to the manufacturer  ’  s instructions. The extracted 
RNA (500 ng) was subject to cDNA synthesis with Taqman Reverse Tran-
scription Reagents (Applied Biosystems) at a fi  nal volume of 20     l. For the 
PCR reactions of various humoral factors, we used mouse-specifi  c and human-
specifi  c primers and probes, respectively (Table S1, available at http://www
.jem.org/cgi/content/full/jem.20070166/DC1). The number of PCR cycles 
needed for 6-carboxyfl  uorescein fl  uorescence to cross a threshold where a 
statistically signifi  cant increase in change in fl  uorescence (threshold cycle 
[CT]) was measured using Lightcycler 3.5 software. Relative RNA expression 
was determined using the formula Rel ExP = 2          CT  , where      CT = CT 
gene of interest    CT GAPDH in experimental samples. To confi  rm the protein 
expression of the genes of interest, immunoblot (Western blot) assays were 
performed by modifi  cation of the procedures described previously (  4  ). In 
brief, protein extracts (100     g per sample) were separated using SDS-PAGE 
(Bio-Rad Laboratories) and electrotransferred onto PVDF membranes (GE 
Healthcare). Samples were probed with the following antibodies: VEGF, 
FGF-2, IGF-I, PDGF-B, and SDF-1 (all from Santa Cruz Biotechnology, 
Inc). ECL or ECL-PLUS (GE Healthcare) was used for detection. Equal 
protein loading was confi  rmed by reprobing with tubulin antibody (EMD). 
  Circulating EPC culture assay 
  EPC culture assay was performed as described previously (  38, 49  ). In brief, 
peripheral blood mononuclear cells isolated from 500     l of blood by density 
gradient centrifugation were cultured in the aforementioned EPC media on 
four-well glass slides. After 4 d in culture, cells were incubated with DiI-labeled 
acetylated LDL (Biomedical Technologies) for 1 h, followed by FITC-
conjugated   Bandeiraea simplicifolia   lectin I (Vector Laboratories). The double-
stained cells, considered EPCs, were counted in 10 randomly selected high-power 
fi  elds under fl  uorescent microscopy, and the number of positive cells was con-
verted to numbers per square millimeter. 
  Flow cytometry cell analysis 
  Single cell suspensions of peripheral blood mononuclear cells were labeled 
with antibodies against FITC-conjugated Sca-1 (Ly6AE), PE-conjugated 
VEGF-R2(LY-73), PE-conjugated c-kit (CD117), and an allophycocyanin-
conjugated lineage cocktail (CD3e, CD11b, Ly-6G, GR-1, CD45R/B220, 
and TER-119; all from BD Biosciences) and analyzed using a FACScan 
(Becton Dickinson) or a MoFlo fl  ow cytometer (Dako) as described previously 
(  4, 47  ). Proper isotype-matched IgG was used as a control. 
  Physiological assessment of LV function 
  Transthoracic echocardiography (15.0-MHz ultraband linear transducer; 
SONOS 5500; Hewlett Packard) was performed before and 2 wk after MI 
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